What is the role of paritaprevir/ritonavir/ombitasvir (Technivie) in the treatment of hepatitis C virus (HCV) infection?

Updated: Dec 09, 2020
  • Author: David C Wolf, MD, FACP, FACG, AGAF, FAASLD; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print


In July 2015, the combination product paritaprevir/ritonavir/ombitasvir (Technivie) received FDA approval. [22] It is used in combination with ribavirin for the treatment of patients with genotype 4 patients without cirrhosis. In the PEARL-1 study, treatment with PrO plus ribavirin resulted in an SVR rate of 100%. Patients treated with PrO without ribavirin achieved an SVR rate of 91%. [23]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!